Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal
Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a new drug candidate from Sosei Heptares.
Neurocrine outlined a deal that provides Sosei Heptares $100 million upfront, R&D expenses and a motherlode of milestones worth up to $2.6 billion if successful. That starting figure closely resembles what the biotech paid Takeda to land 3 programs, including the schizophrenia drug TAK-831, which failed to measure up in the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.